Achillion Reports Positive Data from Phase 2 Study of Danicopan (ACH-4471) in Combination with Eculizumab in PNH Patients who Have an Inadequate Response to Eculizumab Monotherapy at the 61st American Society of Hematology Meeting

– 2.4 g/dL mean increase in hemoglobin at 24 weeks –
– Reduction in blood transfusions from 34 to 1; and improvements in markers of hemolysis –
– Completed End of Phase 2 Meeting; Phase 3 Trial Initiation in early 2020 –